1
|
Murakami Y, Tsukano K, Hirata H, Suzuki K. Evaluation of blood serum iron concentration as an alternative biomarker for inflammation in dairy cows. Biol Trace Elem Res 2023; 201:4710-4717. [PMID: 36622523 DOI: 10.1007/s12011-022-03544-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/25/2022] [Accepted: 12/22/2022] [Indexed: 01/10/2023]
Abstract
This study aimed to clarify the relationship between acute phase protein (APP) concentrations and serum Fe concentrations to determine whether serum iron (Fe) can be clinically applied as a substitute for APPs in cows. One hundred five Holstein-Friesian breed lactating dairy cows were enrolled in this study. Cows with inflammatory diseases were 16 subclinical, and 15 severe mastitis cows, in addition to 15 mild and 16 severe sole ulcer cows. The plasma haptoglobin (HPT), alpha-1 acid glycoprotein (AGP), SAA, serum Fe levels, and other biochemical parameters in the cows were measured. The two-sample t-tests and multiple logistic regression analysis were used to compare the control and inflammatory disease groups. ROC analysis was used to evaluate the ability to diagnose inflammation disease. From the results, the proposed diagnostic cutoff value for plasma SAA and serum Fe concentrations to identify dairy cows with inflammatory diseases based on analyses of ROC curves were set at > 3.65 mg/l and < 120.50 µg/dl, respectively. Therefore, instead of using expensive inflammatory markers to evaluate the inflammatory state at the first treatment day for inflammatory diseases in cow, it shows the useful for screening with serum Fe concentration that can be measured easily and inexpensively as alternative inflammatory biomarkers.
Collapse
Affiliation(s)
- Yoshiki Murakami
- School of Veterinary Medicine, Rakuno Gakuen University, 582 Bunkyodai-Midorimachi, Ebetsu, Hokkaido, 069-8501, Japan
| | - Kenji Tsukano
- Hokkaido Agricultual Mutual Releef Association, 74-2 Higashimae, Hokuto, Hokkaido, 041-1214, Japan
| | - Haruyuki Hirata
- School of Veterinary Medicine, Rakuno Gakuen University, 582 Bunkyodai-Midorimachi, Ebetsu, Hokkaido, 069-8501, Japan
| | - Kazuyuki Suzuki
- School of Veterinary Medicine, Rakuno Gakuen University, 582 Bunkyodai-Midorimachi, Ebetsu, Hokkaido, 069-8501, Japan.
| |
Collapse
|
2
|
Cazanga V, Palma C, Casanova T, Rojas D, Barrera K, Valenzuela C, Acevedo A, Ascui-Gac G, Pérez-Jeldres T, Pérez-Fernández R. Modulation of the Acute Inflammatory Response Induced by the Escherichia coli Lipopolysaccharide through the Interaction of Pentoxifylline and Florfenicol in a Rabbit Model. Antibiotics (Basel) 2023; 12:antibiotics12040639. [PMID: 37107001 PMCID: PMC10135147 DOI: 10.3390/antibiotics12040639] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/22/2023] [Revised: 03/12/2023] [Accepted: 03/22/2023] [Indexed: 04/29/2023] Open
Abstract
BACKGROUND Experimental reports have demonstrated that florfenicol (FFC) exerts potent anti-inflammatory effects, improving survival in a murine endotoxemia model. Considering the anti-inflammatory and immunomodulatory properties of pentoxifylline (PTX) as an adjuvant to enhance the efficacy of antibiotics, the anti-inflammatory effects of the interaction FFC/PTX over the E. coli Lipopolysaccharide (LPS)-induced acute inflammatory response was evaluated in rabbits. METHODS Twenty-five clinically healthy New Zealand rabbits (3.8 ± 0.2 kg body weight: bw), were distributed into five experimental groups. Group 1 (control): treated with 1 mL/4 kg bw of 0.9% saline solution (SS) intravenously (IV). Group 2 (LPS): treated with an IV dose of 5 µg/kg of LPS. Group 3 (pentoxifylline (PTX) + LPS): treated with an oral dose of 30 mg/kg PTX, followed by an IV dose of 5 µg/kg of LPS 45 min after PTX. Group 4 (Florfenicol (FFC) + LPS): treated with an IM dose of 20 mg/kg of FFC, followed by an IV dose of 5 µg/kg of LPS 45 min after FFC administration. Group 5 (PTX + FFC + LPS): treated with an oral dose of 30 mg/kg of PTX, followed by an IM dose of 20 mg/kg of FFC, and, 45 min after an IV dose of 5 µg/kg of LPS was administered. The anti-inflammatory response was evaluated through changes in plasma levels of interleukins (TNF-α, IL-1β and IL-6), C-reactive protein (CRP), and body temperature. RESULTS It has been shown that each drug produced a partial inhibition over the LPS-induced increase in TNF-α, IL-1β, and CRP. When both drugs were co-administered, a synergistic inhibitory effect on the IL-1β and CRP plasma concentrations was observed, associated with a synergic antipyretic effect. However, the co-administration of PTX/FFC failed to modify the LPS-induced increase in the TNF-α plasma concentrations. CONCLUSIONS We concluded that the combination of FFC and PTX in our LPS sepsis models demonstrates immunomodulatory effects. An apparent synergistic effect was observed for the IL-1β inhibition, which peaks at three hours and then decreases. At the same time, each drug alone was superior in reducing TNF-α levels, while the combination was inferior. However, the peak of TNF-α in this sepsis model was at 12 h. Therefore, in rabbits plasma IL-1β and TNF-α could be regulated independently, thus, further research is needed to explore the effects of this combination over a more prolonged period.
Collapse
Affiliation(s)
- Victoria Cazanga
- Pharmacology Laboratory, Department of Clinical Sciences, Faculty of Veterinary Sciences, Universidad de Concepción, Chillan 3820572, Chile
| | - Cristina Palma
- Pharmacology Laboratory, Department of Clinical Sciences, Faculty of Veterinary Sciences, Universidad de Concepción, Chillan 3820572, Chile
| | - Tomás Casanova
- Pharmacology Laboratory, Department of Clinical Sciences, Faculty of Veterinary Sciences, Universidad de Concepción, Chillan 3820572, Chile
| | - Daniela Rojas
- Veterinary Pathology Laboratory, Department of Pathology and Preventive Medicine, Faculty of Veterinary Sciences, Universidad de Concepción, Chillan 3820572, Chile
| | - Karin Barrera
- Pharmacology Laboratory, Department of Clinical Sciences, Faculty of Veterinary Sciences, Universidad de Concepción, Chillan 3820572, Chile
| | - Cristhian Valenzuela
- Pharmacology Laboratory, Department of Clinical Sciences, Faculty of Veterinary Sciences, Universidad de Concepción, Chillan 3820572, Chile
| | - Aracelly Acevedo
- Pharmacology Laboratory, Department of Clinical Sciences, Faculty of Veterinary Sciences, Universidad de Concepción, Chillan 3820572, Chile
| | - Gabriel Ascui-Gac
- Center for Autoimmunity and Inflammation, La Jolla Institute for Immunology, California University, San Diego, CA 92182, USA
| | - Tamara Pérez-Jeldres
- Department of Gastroenterology, Faculty of Medicine, Pontificia Universidad Católica de Chile, Santiago 8331150, Chile
| | - Rubén Pérez-Fernández
- Pharmacology Laboratory, Department of Clinical Sciences, Faculty of Veterinary Sciences, Universidad de Concepción, Chillan 3820572, Chile
| |
Collapse
|
3
|
Tomazi ACCH, Tomazi T, Bringhenti L, Vinhal APA, Rodrigues MX, Bilby TR, Huson HJ, Bicalho RC. Treatment with 2 commercial antibiotics reduced clinical and systemic signs of pneumonia and the abundance of pathogenic bacteria in the upper respiratory tract of preweaning dairy calves. J Dairy Sci 2023; 106:2750-2771. [PMID: 36797182 DOI: 10.3168/jds.2022-22451] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/27/2022] [Accepted: 10/27/2022] [Indexed: 02/16/2023]
Abstract
The aim of this study was to evaluate the effect of therapeutically administered tildipirosin or florfenicol + flunixin meglumine for the treatment of bovine respiratory disease (BRD) accompanied by fever in calves before weaning compared with diseased and untreated animals. As specific objectives, we evaluated the composition of the bacterial microbiota of the upper respiratory tract (URT) and blood and health parameters of the animals. Preweaning Holstein female calves diagnosed with naturally acquired pneumonia were randomly assigned to one of the following experimental groups on the day of diagnosis (d 0): (1) TLD (n = 36): single subcutaneous injection with 4 mg/kg tildipirosin; (2) FLF (n = 33): single subcutaneous injection with an antimicrobial (40 mg/kg florfenicol) combined with a nonsteroidal anti-inflammatory drug (2.2 mg/kg flunixin meglumine); and (3) NEG (n = 35): no treatment within the first 5 d following enrollment. The NEG treatment group was closely monitored for 5 d, and calves were removed from the study following a standardized late treatment protocol, when necessary, to minimize health concerns. Healthy untreated calves (CTR; n = 31) were also selected for the study and used as controls. Blood samples used for biochemical analysis and nasopharyngeal swabs used for evaluation of URT microbiota were collected daily from d 0 until d 5 and then weekly until weaning. Next-generation sequencing of the 16S rRNA gene was used to assess the URT microbiota at the phylum and genus levels. Clinical signs associated with pneumonia and otitis media were assessed daily, as was the need for antibiotic interventions. Calves in the TLD and FLF groups had faster recovery from fever within the first 5 d after enrollment. In addition, antibiotic-treated calves reached the same serum haptoglobin levels as healthy calves on d 2 after diagnosis, whereas calves in the NEG group had higher haptoglobin levels than the CTR group until at least d 5 after BRD diagnosis. Calves in the TLD and FLF groups had a lower risk of treatment for pneumonia (FLF = 22.8%; TLD = 27.7%) from d 5 to weaning than calves in the NEG group (54.7%). Furthermore, FLF treatment had a significantly lower risk of nasal discharge, otitis media, and treatment failure compared with the NEG group, but did not differ from the TLD group. Differences in the composition of the URT microbiota were found between groups, and the genus Mycoplasma was the most abundant in samples collected from the URT of calves with and without pneumonia. Both drugs were effective in reducing the mean relative abundance (MRA) of important genera associated with pneumonia (Mannheimia and Pasteurella), although an increase in Mycoplasma MRA was observed for tildipirosin-treated calves. In conclusion, both drugs were effective in reducing the inflammatory signs of pneumonia and the need for antimicrobial treatment after enrollment compared with no treatment. In addition, both TLD and FLF were effective in reducing the MRA of important bacterial genera associated with pneumonia; however, TLD treatment was associated with increased Mycoplasma MRA compared with healthy and untreated calves.
Collapse
Affiliation(s)
- A C C H Tomazi
- Department of Population Medicine and Diagnostic Sciences, Cornell University, Ithaca, NY 14853
| | - T Tomazi
- Department of Population Medicine and Diagnostic Sciences, Cornell University, Ithaca, NY 14853; Merck Animal Health, Madison, NJ 07940.
| | - L Bringhenti
- Department of Population Medicine and Diagnostic Sciences, Cornell University, Ithaca, NY 14853; FERA Animal Health LLC, College Station, TX 77845
| | - A P A Vinhal
- Department of Population Medicine and Diagnostic Sciences, Cornell University, Ithaca, NY 14853
| | - M X Rodrigues
- Department of Population Medicine and Diagnostic Sciences, Cornell University, Ithaca, NY 14853; FERA Animal Health LLC, College Station, TX 77845
| | - T R Bilby
- Merck Animal Health, Madison, NJ 07940
| | - H J Huson
- Department of Animal Sciences, Cornell University, Ithaca, NY 14853
| | - R C Bicalho
- Department of Population Medicine and Diagnostic Sciences, Cornell University, Ithaca, NY 14853; FERA Animal Health LLC, College Station, TX 77845
| |
Collapse
|
4
|
De Koster J, Tena JK, Stegemann MR. Treatment of bovine respiratory disease with a single administration of tulathromycin and ketoprofen. Vet Rec 2021; 190:e834. [PMID: 34476817 DOI: 10.1002/vetr.834] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/27/2020] [Revised: 05/18/2021] [Accepted: 07/27/2021] [Indexed: 11/05/2022]
Abstract
BACKGROUND The therapeutic strategy of bovine respiratory disease (BRD) often involves a combination of an antibiotic with an anti-inflammatory agent. Aim of this study was to evaluate the clinical effect of a new combination product containing tulathromycin and ketoprofen for the treatment of naturally occurring BRD. METHODS Two hundred and eighty animals were randomized upon diagnosis of BRD. One hundred forty animals each were treated once subcutaneously with tulathromycin-ketoprofen or tulathromycin. Rectal temperature of each animal was measured at 1, 2, 4, 6, 8, 10, 12 and 24 h post-treatment. Individual respiration and depression scores were determined at 6 h post-treatment. Daily rectal temperature, respiration and depression scores were recorded from day 2 to 14 and on day 21. RESULTS The tulathromycin-ketoprofen and tulathromycin treatment group demonstrated a treatment success rate of 94.2% and 95.0%, respectively and a relapse rate of 3.8% and 4.0%, respectively. Tulathromycin-ketoprofen demonstrated superior pyrexia control compared to tulathromycin within the first 24 h following treatment. Tulathromycin-ketoprofen-treated animals demonstrated faster improvement of their clinical symptoms (respiration and depression score). CONCLUSION Efficacy of tulathromycin-ketoprofen for the treatment of BRD was non-inferior to tulathromycin. The combination product clearly exhibited more pronounced fever control than tulathromycin which is considered beneficial for animal welfare.
Collapse
Affiliation(s)
- Jenne De Koster
- Veterinary Medicine Research and Development, Zoetis, Zaventem, Belgium
| | - Jezaniah-Kira Tena
- Veterinary Medicine Research and Development, Zoetis, Kalamazoo, Michigan, USA
| | | |
Collapse
|
5
|
De Koster J, Boucher JF, Tena JK, Gehring R, Stegemann MR. Co-formulation of ketoprofen with tulathromycin alters pharmacokinetic and pharmacodynamic profile of ketoprofen in cattle. J Vet Pharmacol Ther 2021; 45:69-82. [PMID: 34387365 DOI: 10.1111/jvp.12999] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/12/2021] [Accepted: 06/25/2021] [Indexed: 12/01/2022]
Abstract
The current studies aimed to evaluate the pharmacokinetic (PK) and pharmacodynamic (PD) profile and to establish a PK-PD model for ketoprofen in a new fixed combination product containing tulathromycin (2.5 mg/kg) and ketoprofen (3 mg/kg) to treat bovine respiratory disease associated with pyrexia in cattle. Firstly, the effect of different ketoprofen doses as mono-substance (1, 3, and 6 mg/kg subcutaneous) on lipopolysaccharide-induced fever was evaluated which indicated that rectal temperature reduction lasted longer in the calves receiving 3 and 6 mg/kg ketoprofen. Secondly, the PK profile of the combination product was compared with mono-substance products (3 mg/kg subcutaneous and intramuscular). The PK profile of ketoprofen in the combination product was characterized by longer t1/2 , lower Cmax and increased AUC in comparison with mono-substance products. Due to prolonged ketoprofen exposure in the combination product, the pyrexia reducing effect of the combination product lasted longer in a second lipopolysaccharide challenge study in comparison with mono-substance products. Finally, a PK-PD model for the anti-pyretic effect of ketoprofen was developed based on the data from the different studies. The PK-PD model eliminated the need for additional animal experiments and indicated that a 3 mg/kg ketoprofen dose in the combination product provided optimal efficacy.
Collapse
Affiliation(s)
- Jenne De Koster
- Zoetis, Veterinary Medicine Research and Development, Zaventem, Belgium
| | - Joseph F Boucher
- Zoetis, Veterinary Medicine Research and Development, Kalamazoo, MI, USA
| | - Jezaniah-Kira Tena
- Zoetis, Veterinary Medicine Research and Development, Kalamazoo, MI, USA
| | - Ronette Gehring
- Division of Veterinary and Comparative Pharmacology, Faculty of Veterinary Medicine, Institute for Risk Assessment Sciences, Utrecht University, Utrecht, The Netherlands
| | | |
Collapse
|
6
|
Dudek K, Bednarek D, Ayling RD, Kycko A, Reichert M. Preliminary study on the effects of enrofloxacin, flunixin meglumine and pegbovigrastim on Mycoplasma bovis pneumonia. BMC Vet Res 2019; 15:371. [PMID: 31655595 PMCID: PMC6815429 DOI: 10.1186/s12917-019-2122-3] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/22/2019] [Accepted: 10/09/2019] [Indexed: 11/10/2022] Open
Abstract
BACKGROUND Mycoplasma bovis is a causative agent of disease in cattle causing many clinical conditions. Currently there are no commercial M. bovis vaccines in Europe and treatment is difficult with decreased antimicrobial susceptibility of M. bovis field isolates. Using an M. bovis calf infection model the effectiveness of enrofloxacin given alone; in combination with flunixin meglumine, a nonsteroidal anti-inflammatory drug; and a group with an additional treatment of pegbovigrastim, an immunostimulator, was evaluated. RESULTS Enrofloxacin given alone stimulated a strong immune response, reduced the clinical manifestation and lung lessions of the M. bovis infection. In contrast the combination therapy appeared ineffective. CONCLUSIONS In this experiment enrofloxacin given alone appeared to be the most effective treatment of the M. bovis affected calves, whereas co-administration with flunixin meglumine, and pegbovigrastim was not beneficial in this trial.
Collapse
Affiliation(s)
- Katarzyna Dudek
- Department of Cattle and Sheep Diseases, National Veterinary Research Institute, 57 Partyzantów Avenue, 24-100, Pulawy, Poland.
| | - Dariusz Bednarek
- Department of Cattle and Sheep Diseases, National Veterinary Research Institute, 57 Partyzantów Avenue, 24-100, Pulawy, Poland
| | - Roger D Ayling
- Mycoplasma Team, Animal and Plant Health Agency (Weybridge), Woodham Lane, Addlestone, Surrey, KT15 3NB, UK
| | - Anna Kycko
- Department of Pathology, National Veterinary Research Institute, 57 Partyzantów Avenue, 24-100, Pulawy, Poland
| | - Michał Reichert
- Department of Pathology, National Veterinary Research Institute, 57 Partyzantów Avenue, 24-100, Pulawy, Poland
| |
Collapse
|
7
|
Yang F, Lin Z, Riviere JE, Baynes RE. Development and application of a population physiologically based pharmacokinetic model for florfenicol and its metabolite florfenicol amine in cattle. Food Chem Toxicol 2019; 126:285-294. [DOI: 10.1016/j.fct.2019.02.029] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/31/2018] [Revised: 02/14/2019] [Accepted: 02/19/2019] [Indexed: 12/17/2022]
|
8
|
Achard D, Caruso-Vares A, Collin JF, McKelvie J, Reddick D, Ramage C. Treatment of experimentally induced bovine respiratory disease in young calves with a single administration of a combination of florfenicol and meloxicam. Vet Rec 2018; 183:535. [DOI: 10.1136/vr.104795] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/23/2017] [Revised: 07/26/2018] [Accepted: 08/13/2018] [Indexed: 11/03/2022]
|
9
|
Sidhu PK, Waraich GS, Kaur G, Daundkar PS, Sharma SK, Gehring R. Difference in the PK of ceftiofur in the presence and absence of nimesulide and implications for dose determination through PK/PD integration. Small Rumin Res 2018. [DOI: 10.1016/j.smallrumres.2017.12.005] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
10
|
Thiry J, Fournier R, Roy O, Catala M. Evaluation of flunixin meglumine pour-on administration on prostaglandin E 2 concentration in inflammatory exudate after induction of inflammation in cattle. Res Vet Sci 2017; 114:294-296. [PMID: 28605693 DOI: 10.1016/j.rvsc.2017.04.010] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/05/2016] [Revised: 03/24/2017] [Accepted: 04/18/2017] [Indexed: 11/26/2022]
Abstract
The effect of flunixin transdermal pour-on solution (Finadyne® Transdermal; MSD Animal Health) on prostaglandin E2 (PGE2) synthesis in bovine inflammatory exudate was evaluated in a tissue cage model of acute inflammation. Twelve calves were randomly allocated to two-treatment groups over two sequences. Three weeks prior to the first period, sterile hollow perforated polyethylene balls were surgically embedded in the subcutis at four distinct sites in each animal. On the first day of each period, an aseptic inflammation was induced by injecting 0.5mL of a 2% carrageenan solution into the lumen of each tissue cage. Treatment with either flunixin transdermal or negative control (NaCl) immediately followed. 0.5mL of exudate was collected prior to challenge, and at 2, 4, 8, 12, 24, 36 and 48h after challenge. Exudate PGE2 concentrations were analyzed using ultra-high pressure liquid chromatography coupled with tandem mass spectrometry method. Mean PGE2 concentrations were consistently lower in calves treated with flunixin transdermal than those measured in calves treated with negative control, indicating an inhibitory activity on cyclooxygenase. Inhibition was the highest at 8h after treatment, and differences with the negative control were significant at +8, 24, 36 and 48h. The flunixin transdermal formulation was effective in reducing PGE2 concentrations in bovine exudate following an induced inflammation. Its anti-inflammatory action started in the first hours after treatment and lasted up to 48h.
Collapse
Affiliation(s)
- Julien Thiry
- Merck Animal Health, 2 Giralda Farms, Madison, NJ 07940, USA.
| | - René Fournier
- MSD Santé Animale, 7 rue Olivier de Serres, 49071 Beaucouzé, France
| | - Olivier Roy
- CEBIPHAR, 1 rue de la Bodinière, 37230 Fondettes, France
| | - Mathias Catala
- CEBIPHAR, 1 rue de la Bodinière, 37230 Fondettes, France
| |
Collapse
|